SCHEMBL13709366

SCHEMBL13709366

CCC(O)(CC)COc1ccc(C(CC)(CC)c2ccc(C(=O)N(C)C(C)(C)C(=O)O)c(C)c2)cc1C

nearest known ligand 0.57

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
VDR P11473 16/20 0.57
HDAC3 O15379 2/20 0.56
HDAC6 Q9UBN7 2/20 0.56
AR P10275 6/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13709370 0.87 HDAC6 (0.63) VDRHDAC3HDAC6AR
SCHEMBL13709369 0.84 HDAC6 (0.57) VDRHDAC3HDAC6AR
SCHEMBL4507917 0.83 HDAC6 (0.67) VDRHDAC3HDAC6AR
SCHEMBL13709362 0.83 VDR (0.35) VDRHDAC3HDAC6AR
SCHEMBL13709368 0.82 HDAC3 (0.55) VDRHDAC3HDAC6AR
SCHEMBL13709375 0.82 VDR (0.41) VDRHDAC3HDAC6AR
SCHEMBL13709360 0.80 VDR (0.35) VDRHDAC3HDAC6AR
SCHEMBL13709352 0.80 HDAC6 (0.60) VDRHDAC3HDAC6AR
SCHEMBL13203642 0.78 HDAC6 (0.52) VDRHDAC3HDAC6AR
SCHEMBL13709349 0.78 HDAC6 (0.66) VDRHDAC3HDAC6AR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7595345-B2 Vitamin D receptor modulators ELI LILLY AND COMPANY (US) 2009-09-29 US disclosed
US-7595345-B2 Vitamin D receptor modulators ELI LILLY AND COMPANY (US) 2009-09-29 US disclosed
US-20080200552-A1 Vitamin D Receptor Modulators ELI LILLY AND COMPANY (IN) 2008-08-21 US disclosed
US-20080200552-A1 Vitamin D Receptor Modulators ELI LILLY AND COMPANY (IN) 2008-08-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080200552-A1 Vitamin D Receptor Modulators VDR, CYP2R1, CYP24A1 VDR 1/4885HDAC3 1756/4885HDAC6 4464/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.